key: cord-0710082-7w8iegjx authors: Ahadian, Samad; Finbloom, Joel A.; Mofidfar, Mohammad; Diltemiz, Sibel Emir; Nasrollahi, Fatemeh; Davoodi, Elham; Hosseini, Vahid; Mylonaki, Ioanna; Sangabathuni, Sivakoti; Montazerian, Hossein; Fetah, Kirsten; Nasiri, Rohollah; Dokmeci, Mehmet Remzi; Stevens, Molly M.; Desai, Tejal A.; Khademhosseini, Ali title: Micro and nanoscale technologies in oral drug delivery date: 2020-07-22 journal: Adv Drug Deliv Rev DOI: 10.1016/j.addr.2020.07.012 sha: 7a9556ae6201881a9ccd7f3b8af5b940e54fb3f7 doc_id: 710082 cord_uid: 7w8iegjx Oral administration is a pillar of the pharmaceutical industry and yet it remains challenging to administer hydrophilic therapeutics by the oral route. Smart and controlled oral drug delivery could bypass the physiological barriers that limit the oral delivery of these therapeutics. Micro- and nanoscale technologies, with an unprecedented ability to create, control, and measure micro- or nanoenvironments, have found tremendous applications in biology and medicine. In particular, significant advances have been made in using these technologies for oral drug delivery. In this review, we briefly describe biological barriers to oral drug delivery and micro and nanoscale fabrication technologies. Micro and nanoscale drug carriers fabricated using these technologies, including bioadhesives, microparticles, micropatches, and nanoparticles, are described. Other applications of micro and nanoscale technologies are discussed, including the fabrication of devices and tissue engineering models to precisely control or assess oral drug delivery in vivo and in vitro, respectively. Strategies to advance translation of micro and nanotechnologies into clinical trials for oral drug delivery are mentioned. Finally, challenges and future prospects on further integration of micro and nanoscale technologies with oral drug delivery systems are highlighted. Oral delivery has been one of the most commonly used approaches for drug administration in the body due to its high patient compliance, low cost, non-invasiveness, and ease of use (1, 2) . A multitude of therapeutic compounds, including synthetic small molecules and biologics have been administered orally. However, oral drug delivery poses significant challenges to achieving efficient therapeutic outcomes. This is primarily due to the multitude of biological barriers that are present throughout the gastrointestinal (GI) tract that a drug carrier must navigate through. human tissue-on-a-chip models for precision medicine applications. Some limitations of oral drug delivery systems are governed by GI anatomy, physiology, and biochemistry. The skin is the largest interface between the human body and the external environment (18) (19) . In a healthy adult, the human skin has a surface area of approximately 2 m 2 . By comparison, the absorption mechanism of orally delivered drugs in the intestinal epithelium has more chemical and physical restrictions, as it has a much larger surface area (300 -400 m 2 ) (20) . In general, the drug is swallowed and enters the GI tract and it release at the intestine proceeds by diffusing inside the mucus layer as shown in Figure 2 . The mucus in the small intestine is discontinuous, whereas in the stomach and large intestine (colon) there are two layers (21) . The drug is delivered through the mucus layer and from there diffuses through pathways involving a long path through tight junctions (TJs) as well as epithelium cells. This process continues until the drug is carried all the way through the capillary layer covering the epithelium layer. water-oil-water particles. Emulsion techniques allow for the fabrication of particles of varying size, ranging from tens of nanometers to hundreds of microns (37) . The size of the particles is dictated by the sheer imparted during the emulsification process which is affected by the properties of solutions, as well as the concentration of polymer and surfactant in the aqueous phase. The surfactant controls the phase separation behavior during emulsification (38) . PLGAbased reverse emulsions are not able to generate hydrophilic polymer particles in oil phase. Therefore, these emulsions are less common for clinical applications in oral drug delivery where the particle needs to stably traverse aqueous environments. However, in general, some PLGAloaded particles have been used in clinic for other drug delivery systems. Self-assembly fabrication approaches are directed by a variety of noncovalent forces such as hydrophobic-hydrophilic and electrostatic interactions, which can offer more precise control than standard emulsion or precipitation techniques and allow for the fabrication of diverse shapes including spherical, fibrillar, and ellipsoidal particles (39) (40) (41) . Self-assembling systems are typically size-limited to the nanoscale, with the particles commonly reported in the tens of nanometers to low hundreds of nanometers in diameter. Similar to emulsion techniques, selfassembling systems have been used to encapsulate both hydrophobic and hydrophilic cargo for oral drug delivery applications. In electrospinning, a high voltage source is used to make micro-or nanofibers from a polymer solution or melt. An electrostatic interaction between a grounded collector and charged polymer solution is formed when the polymer expelled from a metal needle, forming a cone at the base of the needle called a Taylor cone. A fiber jet is ejected from the Taylor cone as the electric field strength exceeds the surface tension of the liquid. By travelling the fiber jet through the air, the solvent evaporates, consequently results in the deposition of solid polymer fibers on the collector. Fibers generated by this process usually have diameters on the order of some hundred nanometers. The capability to simply generate materials at different sizes in a rapid and simple manner has made a great interest in electrospinning for tissue engineering and drug delivery applications (42, 43) . Researchers have widely used this technology in drug delivery because it is easy to modulate the release profile of drugs based on properties of polymeric materials and it is compatible with a variety of drugs and biopolymers (44) . Photolithography involves the transferring of a photomask's pattern onto a photoresist by exposure to light (1, 45, 46) . The photoresist layer is employed to transfer the pattern to a material after development. The wavelength of light exposure is the dominant limitation of photolithography. High resolution nanostructures can be made using more advanced techniques, such as ion beam lithography and electron beam lithography (33) . Soft lithography is a complementary version of photolithography. While photolithography has worked well to deal with photoresists (47) , soft lithography expands the capabilities of J o u r n a l P r e -p r o o f photolithography. Soft lithography can process a variety of elastomeric materials. Polydimethylsiloxane (PDMS) is commonly used for soft lithography applications due to its properties of biocompatibility, low cost, chemical inertness, low toxicity, mechanical flexibility and durability, and versatile surface chemistry. Additionally, fabricating PDMS devices requires minimal equipment (48, 49 ). Microfluidic systems are capable of handling and transporting small volumes of fluids through microchannels and they can be created with photo and soft lithography. Microfluidics have been used as a great tool for designing drug delivery systems (45, 50) . Drug delivery to target sites can be done in an efficient and well-controlled manner with desired rates using microfluidic platforms via implantation, localization, precise control, automation, and integration of the platform (51) . Microfluidics can fabricate materials with high precision and recapitulate in vivo conditions for drug screening (52) (53) (54) and drug discovery (54, 55) because of its capability to provide physiologically relevant fluid flow (1) . This technology has become an essential part of cellular assays for the analysis of oral drug absorption. channel geometries and flow rate. Microfluidics facilitate the efficient and low cost production of various micro and nanoparticles, composed of different materials and therapeutic agents, with high loading capacity and controlled release at small scale, which minimizes the amount of required reagents, as compared to bulk mixing methods (56) . Microfluidic-based synthesizers are classified as diffusion and droplet-based methods (Figure 4 ) (57) . Hasani-Sadrabadi et al. fabricated a microfluidic device for generating core-shell chitosanbased nanoparticles for oral delivery of hydrophobic anti-cancer drugs to treat colorectal cancer tumors (58). The core of the nanoparticles was composed of a hydrophobic modified N-palmitoyl chitosan for efficient loading of hydrophobic drugs. The core also allowed for the formation of nanoparticles through the self-assembly of chitosan chains, without using a cross-linking agent. The self-assembly of chitosan chains occurred in the first microreactor with hydrodynamically focused flow controlling the mixing time of flow streams. A Tesla micromixer was also designed for efficient mixing and coating of nanoparticles by pH-responsive layer of Eudragit ((pHsensitive poly(methyl methacrylate)) in a controlled manner. The Coanda effect generated in this Tesla-designed micromixer enhances mixing efficiency. It results in deflection of a part of the flow toward the narrow side of the channel and flow of other part through the curved side for an efficient mixing of two flow streams. In the latter study, the thickness of the shell in synthesized particles was controlled by the ratio of sheath flow rate to the main flow rate. Although the generation of particles can be controlled by tuning the flow rate in diffusion-based mixing methods, the continuous flow regime limits efficient diffusion and the reaction between materials boundaries between separate flow streams. In droplet-based techniques, each droplet serves as a microreactor for an independent reaction, resulting in higher production efficiency for J o u r n a l P r e -p r o o f drug-loaded nanocarriers. This method allows for precise control of nanocarrier size, drug loading efficiency, and total amount of nanocarrier produced. Nano-in-micro platforms can be introduced based on droplet-based methods to prepare nanoparticles encapsulated inside microparticles. Araujo et al. produced a multifunctional composite for the oral delivery of a mixture of glucagon-like peptide-1 and an enzymatic inhibitor (dipeptidyl peptidase 4) as antidiabetic drugs for synergistic therapy using droplet-based microfluidic techniques (59) . The glucagon-like peptide-1 was first loaded in different PLGA and mesoporous silicon biomaterials to limit its rapid degradation in the intestine and the resulting nanoparticles were further functionalized by mucoadhesive polymers, such as chitosan and cell penetrating peptides. (64) (65) (66) (67) . Typically, 3D printing works through the digitally-controlled and layer-by-layer deposition of materials to make different 3D constructs and desired geometries without the need for molds or machining (68) (69) (70) , it provides an opportunity to load multiple drugs into a single device and make multifunctional drug delivery systems and dimension-specific drug formulations to attain tunable drug release profiles (63) . More recently, two-photon lithography technologies were designed to offer 3D printing capabilities at nanoscale that could be interesting for oral delivery systems where a nanoparticle has to be of specific shape. The unique physiochemical properties and high surface area to volume ratio of nanoparticles facilitate high loading of drugs into them through encapsulation or formation of chemicalphysical bindings with their functional groups. The stability of some nanoparticles in aqueous physiological environments allows for successful loading and delivery of poorly water-soluble drugs (75) . Additionally, nanoparticles can be functionalized using different targeting or imaging agents in order to be utilized for imaging and targeted drug delivery applications (76) . Specifically, drug delivery using biocompatible nanocarriers has been introduced as an effective solution to overcome some challenges involved in oral drug administration, particularly for drugs with low stability, bioavailability, and solubility. Nanoparticles can protect drugs from the acidic environment of GI and the secretion of mucus to enhance membrane permeability, which promotes drug absorption and bioavailability. Bioadhesive properties of nanoparticles enhance the permeation of drugs by increasing residence time in the GI tract (77) . Microparticles are common oral delivery systems in addition to nanoparticles, and offer the means to improve the bioavailability of pharmaceuticals through the control over shape, size, J o u r n a l P r e -p r o o f geometry, and functional characteristics of the particle (78) (79) (80) (81) . During the past few decades, microparticle technology has been extensively applied for various applications in therapeutic and pharmaceutical fields, such as the delivery of anti-inflammatories (82, 83) , antibiotics (84, 85) , chemotherapeutics (86, 87) , proteins (88) , and vitamins (89, 90) . Microparticle sizes range from 1 to 1000 m and they exist in various structures (91) . Microparticles may be characterized as either homogenous or heterogeneous structures depending on the formulation and processing. Using the techniques described above, drug carriers can be fabricated in multiple size regimes from different materials, with tunable physical and chemical properties. We will briefly describe some of the different classes of carriers, before discussing functionalization strategies and methods of targeting the GI system or systemic bloodstream circulation via oral administration of these carriers. Lipid-based nanoparticles, such as solid lipid nanoparticles (SLNs) and liposomes, are a group of nanoparticles used extensively for oral drug delivery due to their excellent biocompatibility, similarity with biological membranes, and drug loading capacity. Liposomes were the first nanocarriers approved by FDA for clinical use (92) . They are composed of an aqueous core, which encapsulates hydrophilic drugs, and an amphiphilic lipid bilayer, which allows for the loading of hydrophobic drugs (93) (Figure 5a) . Additionally, they can be utilized as the carrier of biomolecules like peptides, antigens or antibodies which are covalently attached to the polyethylene glycol (PEG)-coated (PEGylated) surface of liposomes (Figure 5c ). longer circulation time and enhanced biodistribution (94) . Furthermore, different targeting agents can be conjugated to the external surface of the liposomes for the enhanced targeted delivery of therapeutic agents to specific cells. The encapsulation of hydrophilic drugs and biologics inside of liposomes significantly improves their cellular absorption (95) , (96) . However, the efficiency of conventional phospholipid or cholesterol-based liposomes is seriously affected by instability of their lipid vesicles and phospholipid hydrolysis or oxidation in the GI track. Therefore, chemical and physical functionalization is employed to increase their residence time in the intestine and enhance their stability, as we will discuss in later sections. SLNs contain a monolayer phospholipid shell and a solid lipid core (97) . These nanoparticles can be utilized for encapsulation of lipophilic ingredients and insoluble drugs. SLNs are prepared from synthetic or natural biodegradable and biocompatible lipids, such as fatty acids, triglycerides, steroids, and phospholipids. They have shown high stability in the harsh conditions of the GI, as compared to other lipid nanoparticles, such as liposomes. Functionalizing and noncovalent coating of SLNs with carboxymethyl chitosan can further enhance their stability and drug bioavailability (98) . Several investigations reported higher oral bioavailability of hydrophobic drugs, such as nitrendipine and nimodipine, loaded in SLNs (99), (100) . However, the encapsulation of hydrophilic drugs in SLNs is limited due to the particle's hydrophobic nature. Incorporation of a SLN core with hydrophilic viscosity-enhancing polymers, such as PEG, through a water-oil-water double emulsion method is proposed for higher loading efficiency of hydrophilic drugs in the core of SLNs. In this strategy, the core of orally administered SLNs consists of a solid lipid core and a hydrogen-bonded rich aqueous phase encapsulating insulin, which is either dispersed in the lipid phase or is formed like a central core Of the polymers available, PLGA is one of the most commonly researched polymer for oral drug delivery, owing to its FDA approval (105), biocompatibility, and biodegradability. In particular, PLGA is suitable for oral delivery of water insoluble anti-cancer drugs, such as paclitaxel and curcumin, due to its hydrophobic nature (106) . The encapsulation of hydrophobic anti-cancer drugs in PLGA nanoparticles resulted in enhanced bioavailability of drugs, which is due to improved aqueous stability of loaded drugs in PLGA nanoparticles, compared to free drug, and sustained drug release by degradation of the PLGA nanoparticles (106) . In addition to nanoparticles, different microparticle, polymer-based systems have been introduced for oral drug delivery for in vivo and in vitro studies which are summarized in Table 2 . A natural polymer-based microencapsulation system was proposed by Vasiliu et al. They Another widely used nanocarrier for oral drug delivery is the polymer micelle, which is formed by self-assembly of amphiphilic polymers above the critical micelle concentration. This fabrication process provides a core-shell structure, which allows loading of poorly water soluble drugs in hydrophobic cores with enhanced bioavailability and stability (110) , (111) . For example, an amphiphilic block copolymer consisted of a micellar shell-forming PEG block and a core- Insulin Magnetic nanocrystals and insulin were encapsulated in PLGA microparticles to delay drug transition using a magnetic field. (120) Curcumin PLGA particles with different molecular weights were prepared by an emulsificationsolvent evaporation method to encapsulate curcumin. The results showed that the bioavailability of high molecular weight PLGA particles was better than that of low molecular weight PLGA particles and curcumin. Physicochemical properties and in vivo therapeutic activities of porous and nonporous PLGA microparticles were studied. Ammonium bicarbonate was used to create the porosity and in vivo experiments showed that oral administration of porous microparticles exhibited therapeutic efficacy Controlled release of the drug molecule in the GI tissue was provided with PVA microparticles prepared using different ratios of PVA to starch. Methylcellulose Thymol Methylcellulose and hydroxypropyl methylcellulose phthalate were used to produce Thymol encapsulated microspheres. In vivo pharmacokinetic studies showed that the microparticles could be used for local treatment of intestinal infections. Ethylcellulose Propranolol Ethylcellulose microparticles containing Propranolol hydrochloride were prepared using a modified solvent evaporation method, and its use for the treatment of hypertension was studied. Carboxymethyl cellulose sodium Flurbiprofen Chitosan-coated and uncoated sodium carboxymethyl cellulose and polyvinyl alcohol microspheres were synthesized and crosslinked with Fe 3+ ions. The chitosancoating provided a slower release and a lower burst effect. Progesterone Low methoxy amidated pectin-sodium carboxymethyl cellulose microspheres were prepared, and Zn 2+ and Al 3+ ions were used for crosslinking. The particles were tested in colon-targeted drug delivery. Chitosan Ovalbumin Porous chitosan microparticles, which can be taken up by the epithelium of the Peyer's patches, were synthesized and used as a vaccine delivery system The efficacy of microparticles prepared using different amounts of mucin and alginate on controlled insulin release was assessed. Gelatin Vascular endothelial growth factor (VEGF) Gelatin microparticles were designed for the controlled release of VEGF, and a regular controlled release was achieved by modifying the degree of microparticle crosslinking. Bone morphogenetic protein-2 Gelatin microparticles were evaluated for controlled release of bone morphogenetic protein-2, and the release profiles were compared with PLGA microparticles. Ciprofloxacin Ciprofloxacin, a water-insoluble antimicrobial drug, was encapsulated in gelatin as a result of a one-step process by spray drying an aqueous solution. Polymethacrylic acidpolyethylene glycolchitosan Insulin Surface thiolation was used to increase the drug release performance of hydrogel-based oral insulin delivery systems. (139) Chitosan-carboxymethyl starch Chitosan-carboxymethyl starch particles were synthesized via a casting technique with high encapsulation performance as a drug delivery system for the colon. Chitosan-graftpolyacrylamide Ibuprofen Chitosan-graft-polyacrylamide copolymer was produced by cerium (IV) ammonium nitrate-induced free radical graft polymerization, and the release profile as a function of crosslinker amount and drug to polymer ratio was investigated. Poly(butylmethacrylateco-(2dimethylaminoethyl) methacrylate-co-Micronutrients (iodine, zinc, iron, and vitamins (B2, B12, C, D, and A), methacrylate-comethylmethacrylate) was used to encapsulate different micronutrients, and the (142) J o u r n a l P r e -p r o o f methylmethacrylate) biotin, folic acid, and niacin) encapsulation was shown to provide stability against a variety of factors. In addition to organic nano and microparticles, inorganic particles, including mesoporous silica, gold, silver, iron oxide, quantum dots, carbon nanotubes, and graphene oxide nanoparticles, have found wide applications for oral drug delivery due to their exceptional physiochemical properties (143) , (144), (145) . High stability in aqueous conditions, along with acidic and enzymatic environments (1), feasibility of functionalization (2,3), large surface area with a high loading capacity (4, 5) , enhanced membrane permeability to the cells (6,7), and optical and magnetic properties (8, 9) all suggest promising applications of inorganic nanoparticles not only in drug delivery, but also in bioimaging. However, their clinical applications are restricted by their poor biodegradability and biocompatibility, which requires functionalization with other biomaterials. Functionalization of inorganic nanoparticles with biocompatible ligands can be achieved during their synthesis procedure or after their preparation. Silica nanoparticles, with high porosity and surface area, possess silanol groups, which facilitate their functionalization. For example, silica nanoparticles coated with PEG slowed the release of insulin both in acidic and neutral pH (144) . PEG, chitosan, and alginate coated silicate nanoparticles have also been utilized for oral delivery of insulin to enhance their mucoadhesion and biocompatibility (144), (146) . Poly(amidoamine)functionalized multiwalled carbon nanotubes loaded with hydrophobic therapeutics were modified with a carboxylate group to increase loading capacity and drug dissolution (137) . Insulin-loaded silica nanoparticles ranging from 289 nm to 625 nm showed increased interaction with mucin when coated with chitosan (146). J o u r n a l P r e -p r o o f Micropatches (also called wafers or films) can be designed as drug carriers with a typical size of 2-10 cm 2 and a thickness of 20-500 m (147) (148) (149) . They can be classified as melt away, rapid disintegrating, and sustained-release, referring to their different drug release rates and disintegration times as detailed by Kirsch et al. (150) . The drug release rate can be defined by the polymer used but can also be multilayered with varying disintegration times. Oral patches are usually fabricated with laminated structure, a drug-containing bioadhesive layer, and an impermeable backing layer for increased retention (151) . Encapsulation of drugs in polymeric matrices can be achieved using several methods, such as injection molding, pressing, and 3D printing (153) (154) (155) (156) . Li et al. showed that 3D printing can be utilized to fabricate oral drug delivery devices consisting of various materials with customized designs (Figure 7a ) (160) . FDM was employed for the 3D printing of glipizide-loaded filaments, which were fabricated by melt extrusion of PVA and glipizide (154) . Then, the drug-loaded filament was 3D printed into a tablet shape. The Dendrimers have been extensively studied for oral drug delivery. Dendrimers have complex structure, divided into three parts: core, branch, and terminal groups. Dendrimers are monodispersed, usually symmetric and their molecular weight can be controlled. Additionally, physicochemical properties of dendrimers can be tuned based on their chemical structure, surface functionalization, and core structure. Most importantly, the terminal functional group in dendrimers has significant role as it can be conjugated to various biological active molecules, such as enzymes and antibodies. Polyamidoamine is the most commonly used dendrimer with core structure consists of alkyl diamine and tertiary amine branches. Several drugs, such as clotrimazole, sulfamethoxazole, propranolol, ketoconazole, triclosan have been conjugated to polyamidoamine dendrimer to test their efficacy through oral drug delivery (167) (168) (169) . The latter studies proved that the activity of the drug molecules was significantly increased in conjugation with the dendrimer compared to their pure state. coating nanoparticles with chitosan is an effective method to promote mucoadhesion (173) . Chitosan variants with higher molecular weight have shown better mucoadhesion (174) . Also, chemical modification of chitosan for enhanced mucoadhesion, physiological stability, permeability and bioavailability has been utilized for more efficient oral delivery of various drugs, including anti-cancer and peptide drugs (175), (176) . For instance, thiol functionalization of chitosan exhibited enhanced mucoadhesion, which is due to covalent bonds between the cysteine and thiol groups on mucus glycoproteins (177) . In a similar approach, Tian et al. introduced a two-step flash nanocomplexation process to fabricate core-shell nanoparticles coated with thiolated hyaluronic acid to be utilized for oral insulin delivery (114) . First, a positively charged insulin-loaded nanoparticle core was fabricated through electrostatic interaction between insulin and N-(2-hydroxypropyl)-3-trimethyl ammonium chloride-modified chitosan under turbulent mixing conditions. Subsequently, the prepared positively charged nanoparticle core was coated with polyanionic thiolated hyaluronic acid to synthesize the final product (Figure 5c) . A combination of chitosan with alginate and dextran have also been used for oral delivery of insulin (178) . Combining PLGA nanoparticles with chitosan has also been investigated to improve mucoadhesion of nanoparticles and facilitate their functionalization. In one example, Abd El (115) . In this method, thiolated copolymers with opposite charge were self-assembled in an aqueous solution to form thiolated polymer micelles with the potential for functionalization with targeting agents and improving mucoadhesion and the ability to form redox-sensitive polymer networks (Figure 5d) . These strategies have also been applied to liposomal particles. Coating liposomes with mucoadhesive polymers, such as chitosan through non-covalent interactions increased the residence time and bioavailability of highly hydrophilic drugs with low permeability (181), (182) . Modifying liposomes with thiol groups through functionalization with thiolated polymers (thiomers) imbued liposomes with desirable properties, such as mucoadhesion and enzyme inhibition (183), (184) . In addition to mucoadhesive polymers, conjugation of liposomes with ligands, such as biotin, whose receptors are expressed in the intestine, can enhance the efficacy of conventional liposomes in oral drug delivery (185) . Glycans are binding sites for lectins in the membrane of cells in the GI tract; thus, functionalization of liposomes with lectin is another method to increase mucoadhesion (186) . In addition to mucoadhesive polymers, other hydrophilic polymers such as D-α-tocopheryl J o u r n a l P r e -p r o o f poly(ethylene glycol) 1000 succinate (TPGS) (a PEG-conjugated vitamin E) can be used to enhance the residence time and bioavailability of particles for oral drug delivery. TPGS can prolong the circulation time and cellular uptake of the coated nanoparticles. TPGS increases oral bioavailability by enhancing cell membrane permeability through the inhibition of P glycoproteins (P-gp) (187, 188) . This is particularly important for increasing the oral bioavailability of anticancer drugs. For example, low concentrations of TPGS increased the intestinal permeability of paclitaxel, attributed to the inhibition of P-gp (189) . Therefore, TPGS stands as a potent adjuvant for orally administered chemotherapy. The physical properties of materials, such as mechanical properties, surface area, and surface morphology affect their adhesion properties to surfaces (29) . One of the physical methods to enhance bioadhesion is the utilization of different geometries/shapes of drug carriers. Tao (194) . Additionally, magnetic systems are suggested for more efficient targeted therapy of esophageal cancer using an external magnetic force. Ito et al. prepared magnetic granules composed of ultrafine ferrite and a mixture of bioadhesive polymers containing hydroxypropyl cellulose and Carbopol 934. The granules were administered orally in rabbit models and were guided to the esophagus by applying an external magnet in less than 2 min, and results showed that almost all granules were retained in the target region for 2 h (195) . Rapid degradation, low stability, and poor absorption of drugs in the GI tract can be solved using stable drug delivery capsules to deliver drugs to the stomach, which is dominated by the gastric emptying time of 1-4 hours (196) . In one approach, Jiang et al. studied oral delivery of musselinspired and protein-functionalized electrospun nanofibers for treating gastric cancer (197) . Through the incorporation of a pH-responsive release mechanism, the authors demonstrated doxorubicin release from PCL nanofibers in acidic conditions of the stomach over neutral medium. In addition to the acidic stomach environment, there are a number of other challenges for the delivery of oral peptides, including low permeation through the intestinal epithelium, inactivation, and proteolytic degradation in the GI tract (198) . to bypass these challenges has the capacity to improve bioavailability of a biologically active macromolecule (199) . An illustration of the working mechanism of such microneedle pill is represented in Figure 9 . Recent studies suggest that macromolecule drug delivery may be possible via ingestible self-orienting millimeter-scale applicator (SOMA) capsules, which contain a tiny needle to autonomously position the capsule to engage the GI lining of the stomach in a safe manner to increase retention and enable the escape of insulin cargo from the GI Journal Pre-proof into the bloodstream (196) (Figure 10) . The use of these methods is an alternative to injectable delivery of biologics medications, such as insulin and peptides, and enhances patient convenience, as well as increases safety and efficacy. Microneedle capsules can deliver not only small molecules but also proteins, peptides, vaccines, hormones, and other macromolecules. Traverso et al. successfully deployed a microneedlecontaining device, modeled after current FDA-approved ingestible devices (200), and monitored the administration of insulin in the stomach (198) . Enhancing intestinal drug delivery is primarily driven through the increased adhesion of The proposed microdevice could adhere to the GI tissue due to the presence of nanostructural topology (i.e., nanostraws) on the surface of the device. Thus, the drugs could be locally released over an adjustable time period, while the drugs were not exposed to drug-degrading biomolecules and digestive enzymes. The proposed microdevice can improve the oral absorption, which is of great importance for drugs with poor bioavailability such as insulin. To increase the release of biomolecules from the intestine into the bloodstream, Abramson et al. In a different approach, scientists were inspired by transdermal patches to generate intestinal patches (152) . Intestinal patches are typically millimeters in size and have a mucoadhesive drug reservoir layer, a pH-sensitive layer, and a backing layer. Also, intestinal patches can be composed of water-insoluble polymers, pH-sensitive polymers, colors, fragrances, absorption enhancers, buffer substances, and preservatives (150) . While transdermal patches are designed for drug release of up to one week, intestinal patches are expected to release drugs over the course of hours (213) . Intestinal patches were invented to increase drug bioavailability, reduce the drug disruption by the GI tract, and prevent painful drug injection, such as anticancer drugs for cancer chemotherapy or insulin for diabetes (214) . Figure 11 . In addition to controlling the drug carrier tissue-targeting properties, cellular interactions must also be controlled to improve bioadhesion and drug delivery efficacies. To target intestinal cells and improve cellular bioadhesion, chemical functionalization of materials is often performed. Antibodies and peptides specific for intestinal cells have recently been utilized for functionalization of drug carriers not only to increase adhesion, but also for target based drug delivery to specific types of intestinal cells (23, 103) . In one study, nanoparticles were grafted with trastuzumab (Herceptin, human epidermal growth factor receptor-2 antibody). The antibody-coated nanoparticles showed an increase in uptake by Caco-2 (225) . Another strategy is to use adhesion promoters, such as tethered or linear polymer chains to stimulate bioadhesion in drug delivery (226, 227) . (Figure 13a ) (232) . Nanostructured thin films have also been observed to reversibly loosen epithelial barriers, allowing for increased permeation of antibodies across TJs (Figure 13b ) (233) . In vitro modelling of the GI system is significantly helpful to investigate the performance of various oral drug delivery systems in GI tissues. In particular, in vitro GI tract models allow for the studying of drug permeation across biological barriers, as well as studying complex hostmicrobe interactions, while decreasing the costs and ethical issues involved with preclinical animal studies (235) . The physiological environment of the GI tract, including its functions and dynamic conditions, makes it a challenging organ to be modeled in vitro. Several in vitro models, such as organoids, trans-well co-culture, and macroscale bioreactors have been developed to study the GI tract and are reviewed in previous literature (236) . Here, we review systems that use microscale or nanoscale approaches to recapitulate the topography, motility, and flow present Organ-on-a-chip platforms often provide a chamber to colonize cells in a specific arrangement that resembles the architecture of designed tissues or organs and mimics the physiological function of tissues or organs in a microfluidic system (243, 244) . Kimura et al. developed a micro pumping system on-a-chip to model the gut epithelial using Caco-2 cells (Figure 14) . The device was used to investigate the perfusion and transportation of fluorescent compounds for applications in drug toxicity (245) . In further advancement of GI modeling on a chip, Imura et al. made a microchip-based system using Caco-2 cells to test drug absorption (246) . They also developed two organs on-a-chip system using Caco-2 cells for intestine and HepG2 (liver hepatocellular) cells for liver. The intestinal absorption and hepatic metabolism were tested to demonstrate the feasibility of their device for in vitro assays (247) . In another work, Bricks et al. Figure 15a ) and functional gut epithelium and endothelium layers with TJs ( (Figure 15b) .). This system also provided increased transcriptional similarities to the human duodenum. Taken together, the abovementioned studies are the most advanced micro-physiological models of the GI tract to date (258) Although the inclusion of a 3D and mature tissue composed of ECM, muscle cells, vasculature, and capillaries is missing from those models and would help to create a more biomimetic model of human GI tract. However, such simplified microphysiological models of GI tissues can be used to tackle challenges in oral drug delivery and improve our knowledge about the GI action in diverse microenvironments. J o u r n a l P r e -p r o o f It is crucial to push highly advanced drug delivery systems and devices towards clinical applications. Nanocarriers were first used in clinical trials in the 1960s to deliver small molecules that have poor pharmacokinetic profile, low solubility, and high off-target toxicity (259) . Among the developed particles for oral drug delivery, some polymer-based particles have been approved in clinical studies, and several liposomal formulations are under clinical investigations (260) . Additionally, other nanoparticle carriers, such as silica nanoparticles and calcium phosphate nanoparticles have been used in oral drug delivery and have begun to see translation into clinical trials (261) . These nanocarriers have been primarily used to deliver insulin, as well as small lipophilic peptides (~1-2 kDa molecular weight) with a cyclic structure, which are resistive to peptidase degradation. Oral administration is a pillar of pharmaceutical industry. Currently 62% of FDA-approved drugs are orally administered drugs (262) , thanks to ease of administration and high patient acceptance. While small hydrophobic molecules have been successful in oral administration, hydrophilic small molecules or peptides and proteins are yet to find their way to the clinical translation. Indeed, there is an unmet need for the delivery of proteins and peptides for which oral bioavailability is as low as <2% with current technologies (22) . Micro and nanotechnology have been showing to be promising to overcome these barriers. Although many microfabricated drug delivery systems are close to clinical trials, only a few formulations have seen translation into the clinic and numerous challenges remain for the future oral practice (263) . Poor bioavailability has been the major bottleneck of translation of micro and nano technologies for oral delivery. Some practical and simple approaches have been proposed to tackle this problem. For example, nanoparticles can be coated with hydrophilic polymers, such as chitosan and PEG, and TPGS (a PEG-conjugated vitamin E) or can be synthesized with these polymers to further incorporate hydrophilic elements in the polymeric nanoparticles (267) . As a result, the permeability, solubility, stability, and thereby oral bioavailability of nanoparticles are enhanced. Another important challenge for orally administered formulations is that nano-and microfabrication come at a cost that must be justified to make a product commercially costeffective. This is achievable with high-throughput emulsion or self-assembly fabrication methods. However, more advanced microfabricated systems (3D printed or lithography enabled casting), have typically a complex engineering design and low-throughput manufacturing processes that result in high cost of fabrication (29) , (268) , (269) , (170) . For example, the current workflow for 3D printed drug delivery systems is multi-step (3D printing, drug loading, sealing, substrate release) and involves expensive equipment (3D printer, inkjet printer, spray coater) (270) . Recently, rapid and large-scale 3D printing was achieved using a mobile liquid interface that minimize heat buildup (271) . The evolution of such technology to print micro-scale elements in high-throughput could enable the progress of application of oral deliveries. Expensive biologicals are frequently encapsulated in micro and nano-fabricated systems. Interestingly, a daily capsule semaglutide requires a 100 times higher dose and more frequent administration, to achieve a similar efficacy compared to its weekly injection counterpart for the treatment of type 2 diabetes. A study was conducted to confirm that the additional costs incurred to produce extra semaglutide for the oral formulation would still generate a cost-effective oral formulation, given the greater quality of life experienced by the patients receiving the daily capsules (272) . This study testifies the need to carefully assess the dosing frequency against the efficacy when a molecule is selected for encapsulation in micro and nano-fabricated systems. This work also teaches the importance of direct comparison of oral delivery to other routes of administration. Of particular interest is the applications of micro-and nanoscale technologies for delivery of J o u r n a l P r e -p r o o f therapies in preclinical and clinical trials for coronavirus disease 2019 . The outbreak of COVID-19 is considered as one of the deadliest diseases that has caused the death of approximately 550,000 people worldwide so far. Antiviral drugs, such as remdesivir, chloroquine, and hydroxychloroquine have been proposed as promising drug candidates for treating coronavirus disease (273) (274) (275) . These antiviral drugs have been administered orally to inhibit virus infection with mild to moderate doses daily for a long time, which causes the adverse effects in patients. In order to overcome such issues, we suggest employing micro and nanotechnology-based drug delivery approaches to increase the efficacy of these drugs to prevent coronavirus infection. Improving the standardization of preclinical parameters and procedures, including biodistribution, toxicity, protein adsorption, and device removal (27, 269) will enable faster translation of technologies into the clinic. Despite these challenges, the opportunities for improving oral drug delivery using micro and nanoscale technologies is immense, and therefore the field should continue the push for translation into large animal models and eventual clinical trials. During the past decade, researchers have had great leverage to create nano and microdevices that enable oral administration of different biomolecules. Indeed, the clinical translation of nanotechnology for drug delivery through the intravenous route, gave us a deep understanding of such systems. In parallel, the great progress of microfabrication methods was leveraged to serve J o u r n a l P r e -p r o o f the oral administration field. This progress was only recently reflected to marketed products. To unlock the full potential of such technologies, researchers should focus on inventing methods that would ensure robust manufacturing scale-up and solid proof of efficacy. It is crucial to push highly advanced drug delivery systems and devices towards clinical applications as they could be leading to an evolution of pharmaceutical industry towards more patient-friendly oral administration. Microfabrication technologies for oral drug delivery Recent technological advances in oral drug delivery-a review DNA nanomaterials for preclinical imaging and drug delivery Protein-based nanomedicine platforms for drug delivery Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers Softening the rule of five-where to draw the line? Bioorganic & medicinal chemistry Correlates of insulin injection omission Oral insulin delivery: existing barriers and current counter-strategies Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies Facile and rapid generation of 3D chemical gradients within hydrogels for high-throughput drug screening applications Development of functional biomaterials with micro-and nanoscale technologies for tissue engineering and drug delivery applications Microfabricated particulate drug-delivery systems Drug delivery and tissue engineering Controlled drug delivery systems: past forward and future back Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles Skin barrier and transdermal drug delivery Skin tissue engineering-in vivo and in vitro applications. Advanced drug delivery reviews Skin barrier and transdermal drug delivery The outer mucus layer hosts a distinct intestinal microbial niche Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers Approaches for enhancing oral bioavailability of peptides and proteins Polymeric Nanomaterials. Nanocarriers for Drug Delivery2019 Materials for oral delivery of proteins and peptides Oral delivery of biologics for precision medicine Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins Micro/nanofabricated platforms for oral drug delivery Moving smaller in drug discovery and delivery Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA Microfluidic devices for biomedical applications Design, fabrication and characterization of drug delivery systems based on lab-on-a-chip technology Functional polymer microspheres. Progress in polymer science Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier An Overview of Pickering Emulsions: Solid-Particle Materials, Classification, Morphology, and Applications Microspheres for controlled release drug delivery Advances in fabrication of emulsions with enhanced functionality using structural design principles Self-assembling materials for therapeutic delivery Advanced drug delivery devices via selfassembly of amphiphilic block copolymers Epub 2006/11/17 Electrospinning: Applications in drug delivery and tissue engineering Electrospun Nanofibers in Oral Drug Delivery Electrospun polymeric nanofibers: New horizons in drug delivery Microfluidics for Advanced Drug Delivery Systems Multiplexed instrument-free meningitis diagnosis on a polymer/paper hybrid microfluidic biochip Microfabrication meets microbiology Blood Cells Separation and Sorting Techniques of Passive Microfluidic Devices: From Fabrication to Applications. Micromachines (Basel) Exploring contraction-expansion inertial microfluidic-based particle separation devices integrated with curved channels Recent advances of controlled drug delivery using microfluidic platforms Microfluidic cell culture systems for drug research Microscale technologies for tissue engineering and biology Microfluidics for drug discovery and development: from target selection to product lifecycle management Lab-on-a-chip: microfluidics in drug discovery Microfluidic spinning of micro-and nano-scale fibers for tissue engineering Microfluidics-assisted in vitro drug screening and carrier production Microfluidic Manipulation of Core/Shell Nanoparticles for Oral Delivery of Chemotherapeutics: A New Treatment Approach for Colorectal Cancer Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs Fabrication of a multifunctional nano-in-micro drug delivery platform by microfluidic templated encapsulation of porous silicon in polymer matrix Microfluidic templated mesoporous silicon-solid lipid microcomposites for sustained drug delivery Microfluidic assembly of a nano-in-micro dual drug delivery platform composed of halloysite nanotubes and a pH-responsive polymer for colon cancer therapy Printing Technology in Customized Drug Delivery System: Current State of the Art, Prospective and the Challenges Formulation strategies for solid oral dosage form using 3D printing technology: A mini-review 3D-Printed Ultra-Robust Surface-Doped Porous Silicone Sensors for Wearable Biomonitoring Permeability and mechanical properties of gradient porous PDMS scaffolds fabricated by 3D-printed sacrificial templates designed with minimal surfaces Drop-on-demand high-speed 3D printing of flexible milled carbon fiber/silicone composite sensors for wearable biomonitoring devices Bioinks and bioprinting technologies to make heterogeneous and biomimetic tissue constructs The emergence of 3D bioprinting in organ-on-chip systems Three-Dimensional Bioprinting of Functional Skeletal Muscle Tissue Using Gelatin Methacryloyl-Alginate Bioinks Personalised dosing: printing a dose of one's own medicine 3D Printing technologies for drug delivery: a review 3D printed drug delivery and testing systems-a passing fad or the future? Advanced drug delivery reviews Targeted delivery of docetaxel by use of transferrin/poly (allylamine hydrochloride)-functionalized graphene oxide nanocarrier Incorporation of Graphene Quantum Dots, Iron, and Doxorubicin in/on Ferritin Nanocages for Bimodal Imaging and Drug Delivery Nanocarriers for oral drug delivery Nanoparticle-inmicroparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination Chronakis IS. Development of electrosprayed mucoadhesive chitosan microparticles Nanostructured mucoadhesive microparticles to enhance oral drug bioavailability Customizing poly(lactic-co-glycolic acid) particles for biomedical applications Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease Effects of process parameters on the properties of biocompatible ibuprofen-loaded microcapsules Controlled release of vancomycin from PCL microcapsules for an ophthalmic application Preparation of azithromycin microcapsules by a layer-bylayer self-assembly approach and release behaviors of azithromycin The emerging role of exosome and microvesicle-(EMV-) based cancer therapeutics and immunotherapy Delivery of chemotherapeutic drugs in tumour cell-derived microparticles New alginate microcapsule system for angiogenic protein delivery and immunoisolation of islets for transplantation in the rat omentum pouch Drug Delivery Systems for Vitamin D Supplementation and Therapy Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery Ligand-targeted liposome design: challenges and fundamental considerations Liposomes as potential drug carrier systems for drug delivery. Application of nanotechnology in drug delivery Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption Oral delivery of peptides and proteins using lipid-based drug delivery systems Solid lipid nanoparticles: production, characterization and applications. Advanced drug delivery reviews Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery Bioadhesion: new possibilities for drug administration? Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats Adsorption of cefotaxime sodium salt on polymer coated ion exchange resin microparticles: Kinetics, equilibrium and thermodynamic studies A novel thermo-induced selfbursting microcapsule with magnetic-targeting property pH-responsive and enzymatically-responsive hydrogel microparticles for the oral delivery of therapeutic proteins: Effects of protein size, crosslinking density, and hydrogel degradation on protein delivery Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil Reverse micelle-loaded lipid nanocarriers: a novel drug delivery system for the sustained release of doxorubicin hydrochloride Uniform core-shell nanoparticles with thiolated hyaluronic acid coating to enhance oral delivery of insulin Thiol-functionalized polymeric micelles: from molecular recognition to improved mucoadhesion Preliminary study of oral polylactide microcapsulated insulin in vitro and in vivo Development of lovastatin-loaded poly(lactic acid) microspheres for sustained oral delivery: in vitro and ex vivo evaluation Development of biodegradable microcapsules as carrier for oral controlled delivery of amifostine The formulation and immunisation of oral poly(DL-lactide-co-glycolide) microcapsules containing a plasmid vaccine against lymphocystis disease virus in Japanese flounder (Paralichthys olivaceus) Magnetically responsive polymeric microparticles for oral delivery of protein drugs Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice Porous Polymeric Microparticles as an Oral Drug Platform for Effective Ulcerative Colitis Treatment Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery PCL/PHBV microparticles as innovative carriers for oral controlled release of manidipine dihydrochloride Novel Starch-PVA Polymer for Microparticle Preparation and Optimization Using Factorial Design Study Encapsulation and modified-release of thymol from oral microparticles as adjuvant or substitute to current medications Preparation and In Vitro Evaluation of Ethylcellulose and Polymethacrylate Resins Loaded Microparticles Containing Hydrophilic Drug Chitosan coated-and uncoated-microspheres of sodium carboxymethyl cellulose/polyvinyl alcohol crosslinked with ferric ion: flurbiprofen loading and in vitro drug release study Amidated pectin/sodium carboxymethylcellulose microspheres as a new carrier for colonic drug targeting: Development and optimization by factorial design Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations Development and in vitro/in vivo evaluation of Zn-pectinate microparticles reinforced with chitosan for the colonic delivery of progesterone Mesoporous, degradable hyaluronic acid microparticles for sustainable drug delivery application Encapsulation of curcumin in polysaccharide-based hydrogel beads: Impact of bead type on lipid digestion and curcumin bioaccessibility Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin In vitro and in vivo release of vascular endothelial growth factor from gelatin microparticles and biodegradable composite scaffolds Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2 Development and optimization of ciprofloxacin-loaded gelatin microparticles by single-step spray-drying technique Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery Synthesis and in vitro evaluation of carboxymethyl starch-chitosan nanoparticles as drug delivery system to the colon Ibuprofen microencapsulation within acrylamide-grafted chitosan and methylcellulose interpenetrating polymer network microspheres: Synthesis, characterization, and release studies A heat-stable microparticle platform for oral micronutrient delivery Emerging micro-and nanotechnology based synthetic approaches for insulin delivery Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery Incorporation of Carvedilol into PAMAM-functionalized MWNTs as a sustained drug delivery system for enhanced dissolution and drug-loading capacity. asian journal of pharmaceutical sciences Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models Pre-clinical evaluation of novel mucoadhesive bilayer patches for local delivery of clobetasol-17-propionate to the oral mucosa Intestinal iontophoresis from mucoadhesive patches: a strategy for oral delivery Oral delivery of macromolecules using intestinal patches: applications for insulin delivery An overview of intestinal wafers for oral drug delivery Drug delivery from the oral cavity: a focus on mucoadhesive buccal drug delivery systems Patches for improving gastrointestinal absorption: an overview 3D printed oral solid dosage forms containing hydrochlorothiazide for controlled drug delivery Preparation and investigation of controlled-release glipizide novel oral device with three-dimensional printing A 3D printed bilayer oral solid dosage form combining metformin for prolonged and glimepiride for immediate drug delivery Ink-jet printing versus solvent casting to prepare oral films: Effect on mechanical properties and physical stability 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles 3D printed multicompartment capsular devices for two-pulse oral drug delivery 3D printing by fused deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of drugs 3D Printing of Medicines: Engineering Novel Oral Devices with Unique Design and Drug Release Characteristics Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy Three-Dimensional Printing of Carbamazepine Sustained-Release Scaffold Polymer-filled microcontainers for oral delivery loaded using supercritical impregnation Supercritical impregnation of polymer matrices spatially confined in microcontainers for oral drug delivery: Effect of temperature, pressure and time Fabrication of particulate Reservoir-Containing, capsulelike, and Self-Folding polymer microstructures for drug delivery From concept to in vivo testing: Microcontainers for oral drug delivery The use of a dendrimerpropranolol prodrug to bypass efflux transporters and enhance oral bioavailability PAMAM dendrimers for the delivery of the antibacterial Triclosan Hydrogel of ketoconazole and PAMAM dendrimers: formulation and antifungal activity Novel engineered systems for oral, mucosal and transdermal drug delivery Microfabricated drug delivery systems: from particles to pores Enhanced gastrointestinal absorption of N3-O-toluylfluorouracil by cationic solid lipid nanoparticles Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin Preparation of poly(lactic-co-glycolic acid) and chitosan composite nanocarriers via electrostatic self assembly for oral delivery of insulin Chitosan-based gastrointestinal delivery systems Methylated N-(4-N,N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery Mucoadhesive and cohesive properties of poly (acrylic acid)-cysteine conjugates with regard to their molecular mass Glutathione and thiolated chitosan inhibit multidrug resistance Pglycoprotein activity in excised small intestine Biotinylated liposomes as potential carriers for the oral delivery of insulin Investigation of lectin-modified insulin liposomes as carriers for oral administration Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access Vitamin E TPGS as a molecular biomaterial for drug delivery Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo Micromachined devices: the impact of controlled geometry from celltargeting to bioavailability From micro to nano contacts in biological attachment devices Fabrication of particulate reservoir-containing, capsulelike, and self-folding polymer microstructures for drug delivery Microfabricated microneedles: a novel approach to transdermal drug delivery Polymeric microspheres for drug delivery to the oral cavity: an in vitro evaluation of mucoadhesive potential A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods An ingestible self-orienting system for oral delivery of macromolecules Mussel-inspired protein-mediated surface functionalization of electrospun nanofibers for pH-responsive drug delivery Microneedles for drug delivery via the gastrointestinal tract Microneedle patch drug delivery in the gut An ingestible self-orienting system for oral delivery of macromolecules Self-propelled and targeted drug delivery of poly (aspartic acid)/iron-zinc microrocket in the stomach Micromotor-enabled active drug delivery for in vivo treatment of stomach infection Bottom-Up Fabrication of Multilayer Enteric Devices for the Oral Delivery of Peptides Fabrication of Sealed Nanostraw Microdevices for Oral Drug Delivery A luminal unfolding microneedle injector for oral delivery of macromolecules Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability pH-triggered drug release from biodegradable microwells for oral drug delivery Stimuli-responsive theragrippers for chemomechanical controlled release Intestinal patch systems for oral drug delivery Oral Drug Delivery Technologies-A Decade of Developments Nanoparticles incorporated in bilaminated films: a smart drug delivery system for oral formulations Intestinal mucoadhesive devices for oral delivery of insulin Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers Retention and transit of intestinal mucoadhesive films in rat small intestine Intestinal mucoadhesive devices for oral delivery of insulin. Bioengineering & translational medicine Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: an in vitro/in vivo evaluation in induced colitis in rat Influence of natural polymer coating on novel colon targeting drug delivery system Electrospun medicated shellac nanofibers for colon-targeted drug delivery Sealing liquid-filled pectinate capsules with a shellac coating Electrospun coreshell structured nanofilm as a novel colon-specific delivery system for protein Multifunctional poly(D,L-lactide-coglycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption Microfabricated devices for enhanced bioadhesive drug delivery: attachment to and small-molecule release through a cell monolayer under flow Bioadhesive poly(methyl methacrylate) microdevices for controlled drug delivery Synthesis of cytoadhesive poly(methylmethacrylate) for applications in targeted drug delivery PEGylated silicon nanowire coated silica microparticles for drug delivery across intestinal epithelium Shape effect in the design of nanowire-coated microparticles as transepithelial drug delivery devices Nanostructure-mediated transport of biologics across epithelial tissue: enhancing permeability via nanotopography Reversible inhibition of efflux transporters by hydrogel microdevices Functional cell models of the gut and their applications in food microbiology-a review Advances and Current Challenges in Intestinal in vitro Model Engineering: A Digest Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay and drug development technologies Engineering mesenchymal stem cell spheroids by incorporation of mechanoregulator microparticles Magnetic manipulation and spatial patterning of multi-cellular stem cell aggregates Probing the luminal microenvironment of reconstituted epithelial microtissues Collagen microparticle-mediated 3D cell organization: a facile route to bottom-up engineering of thick and porous tissues Human intestinal spheroids cultured using Sacrificial Micromolding as a model system for studying drug transport Microfluidic organs-on-chips Enhancement of label-free biosensing of cardiac troponin I. Label-free Biomedical Imaging and Sensing (LBIS) 2020; 2020: International Society for Optics and Photonics An integrated microfluidic system for long-term perfusion culture and on-line monitoring of intestinal tissue models A microfluidic system to evaluate intestinal absorption Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism, and bioactivity Development of a new microfluidic platform integrating co-cultures of intestinal and liver cell lines A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies A pumpless body-on-a-chip model using a primary culture of human intestinal cells and a 3D culture of liver cells Microscale Bioreactors for in situ characterization of GI epithelial cell physiology Microfluidic gut-on-a-chip with three-dimensional villi structure Amplitude-dependent modulation of brush border enzymes and proliferation by cyclic strain in human intestinal Caco-2 monolayers Cyclic stretch disrupts apical junctional complexes in Caco-2 cell monolayers by a JNK-2-, c-Src-, and MLCK-dependent mechanism Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert opinion on drug delivery Progress in nanomedicine: approved and investigational nanodrugs. Pharmacy and Therapeutics Oral delivery of biologics for precision medicine A comprehensive map of FDA-approved pharmaceutical products Micro and nano-fabrication of biodegradable polymers for drug delivery Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials Pharmaceutical nanotechnology for oral delivery of anticancer drugs Nano/microscale technologies for drug delivery Nano-and microfabrication for overcoming drug delivery challenges 3D Printing of Reservoir Devices for Oral Drug Delivery: From Concept to Functionality through Design Improvement for Enhanced Mucoadhesion Rapid, large-volume, thermally controlled 3D printing using a mobile liquid interface Quantifying the value of orally delivered biologic therapies: a cost-effectiveness analysis of oral semaglutide Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Compassionate use of remdesivir for patients with severe Covid-19